Abcuro Presents the P-II/III (MUSCLE) Study Data on Ulviprubart for Inclusion Body Myositis at GCOM 2026

Why It Matters

IBM lacks disease‑modifying treatments; any signal of slowed progression could reshape therapeutic options and attract regulatory attention.

Key Takeaways

• 272 IBM patients randomized to two doses or placebo
• Overall trial showed limited efficacy across all participants
• High‑severity subgroup halved disease progression rate
• Abcuro plans FDA discussions to advance ulviprubart

Pulse Analysis

Inclusion body myositis remains one of the most intractable neuromuscular disorders, affecting roughly 5 per 100,000 adults and leading to progressive weakness that no approved drug can halt. Ulviprubart, a recombinant follistatin‑derived protein, works by antagonizing myostatin pathways, theoretically preserving muscle mass and function. The MUSCLE trial, a combined Phase II/III effort, therefore represented a pivotal test of whether biologic modulation of muscle growth can translate into clinically meaningful outcomes for a disease that has long eluded effective therapy.

The trial’s primary endpoint—change in the IBM Functional Rating Scale over 76 weeks—showed only a modest advantage for both dose levels versus placebo in the overall population (1.7‑point vs 2.4‑point decline for low dose; 2.1‑point vs 2.4‑point for high dose). However, a prespecified subgroup with baseline IBMFRS scores of 29 or higher displayed an approximate 50% slowing of decline, suggesting that patients with more advanced disease may derive greater benefit. Compared with competing pipelines, such as Otsuka’s anti‑complement therapy for IgA nephropathy, ulviprubart’s signal is modest but noteworthy because it targets a fundamentally different mechanism—muscle regeneration rather than immune modulation.

Regulatory implications hinge on whether the FDA will accept the subgroup data as sufficient for accelerated pathways or require a larger confirmatory trial. If approved, ulviprubart could capture a multi‑billion‑dollar niche, given the limited treatment landscape and the high unmet medical need. Investors will watch Abcuro’s upcoming discussions with the agency closely, as a positive outcome could catalyze further financing and partnership opportunities, while also setting a precedent for biologic approaches in rare neuromuscular diseases.